EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exploring the Antibiofilm Potential of Naringin Against Enterobacter hormaechei : Experimental and Computational Insights

Gopika Babu, Parvathi Vaikkathillam, Pooja P Rajan, Devi Jayakumar, Ramya R Prabhu, Praveen Kumar

APMIS · 2025-12 · 133 (12)

DOI: 10.1111/apm.70124 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Biofilms pose a significant threat to public health due to their role in antibiotic‐resistant infections, including urinary tract infections, cystic fibrosis, and infective endocarditis. Enterobacter hormaechei , a Gram‐negative bacterium within the Enterobacter cloacae complex (ECC), is a known biofilm‐former that contributes to infections in the urinary tract, soft tissues, and medical devices. This study investigates the antibiofilm activity of naringin (NA), a flavonoid derived from naringenin, against E. hormaechei using various assays. Minimum Inhibitory Concentration (MIC) assay revealed that NA inhibits planktonic bacterial growth, with an MIC value of 4.096 mg/mL. Crystal Violet (CV) assay revealed a significant reduction in biofilm formation at NA concentrations of 0.5 mg/mL, 1 mg/mL, and 1.5 mg/mL compared to controls. Fluorescence microscopy further confirmed a decrease in bacterial population and disruption of biofilm architecture following NA treatment. In silico analysis was conducted to investigate the potential molecular interactions of NA with the biofilm regulatory proteins MrkB and FimA. The results indicated that NA might effectively inhibit biofilm formation in E. hormaechei by targeting these two key proteins involved in pilus biogenesis and bacterial adherence. These findings suggest that NA could serve as a potential therapeutic agent against E. hormaechei ‐associated infections.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →